CytoMed Therapeutics Limited
CytoMed Therapeutics Limited (GDTC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
gdtc · stock forecast · 1 analysts (3M) · FMP · updated May 10, 2026
Analyst Rating & Consensus
Based on 1 Wall Street analysts in the past 3 months
Buy
1 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.15
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.21 | ↑ 4.95% |
1-day model range: $1.19–$1.23. Peak: $1.23 (+4.95%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -50.0% |
| 2028 | $0 | -62.5% |
| 2029 | $0 | -67.2% |
| 2030 | $0 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · GDTC · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-10-10 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2024-06-11 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
| 2023-12-04 | Benchmark | Maintains | Speculative Buy→Speculative Buy |
Wall Street analysts have recently issued updated ratings on CytoMed Therapeutics Limited (GDTC) stock. Of the recent 3 rating actions, 0 were upgrades and 0 were downgrades. 1 analysts currently cover GDTC.
Analyst Recommendation Trends
GDTC analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↑ 0.0% YoY
Revenue Next Year
$1M
↑ 9.8% YoY
EPS This Year
$-0.26
EPS Next Year
$-0.15
↓ 42.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast GDTC EPS of $-0.26 for the current fiscal year, based on estimates from 1 analysts. The GDTC revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The GDTC stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus GDTC price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The GDTC short-term stock prediction for tomorrow is $1.21 (+4.95%). The GDTC stock price prediction for 2027 estimates an average of $1. The GDTC stock prediction for 2030 projects a range of $0–$0.
CytoMed Therapeutics Limited trades on NASDAQ under the ticker GDTC. The GDTC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
GDTC forecast · 8 questionsAccording to 1 Wall Street analysts, the average 12-month GDTC price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.15.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.